CH489473A - Process for the preparation of alkaloid or antibiotic salts of meta- or para-sulfobenzoyl-hydrazones - Google Patents

Process for the preparation of alkaloid or antibiotic salts of meta- or para-sulfobenzoyl-hydrazones

Info

Publication number
CH489473A
CH489473A CH1786969A CH1786969A CH489473A CH 489473 A CH489473 A CH 489473A CH 1786969 A CH1786969 A CH 1786969A CH 1786969 A CH1786969 A CH 1786969A CH 489473 A CH489473 A CH 489473A
Authority
CH
Switzerland
Prior art keywords
sulfobenzoyl
para
alkaloid
salt
meta
Prior art date
Application number
CH1786969A
Other languages
French (fr)
Inventor
Girard Andre
Ray Andre
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR88828A external-priority patent/FR1526955A/en
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of CH489473A publication Critical patent/CH489473A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/57Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C07C309/59Nitrogen analogues of carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70Nitro radicals
    • C07D307/71Nitro radicals attached in position 5
    • C07D307/72Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2
    • C07D307/74Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2 by hydrazino or hydrazono or such substituted radicals
    • C07D307/75Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2 by hydrazino or hydrazono or such substituted radicals having carboxylic acyl radicals or their thio or nitrogen analogues directly attached to the hydrazino or hydrazono radical, e.g. hydrazides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

  



   Procédé de préparation de sels d'alcaloïdes ou d'antibiotiques de   méta-ou    para-sulfobenzoyl-hydrazones
 L'invention est relative à un procédé de préparation de nouveaux sels d'alcaloïdes et d'antibiotiques des métaou para-sulfobenzoyl-hydrazones de formule générale 1 :
EMI1.1     
 dans laquelle X représente un alcaloïde ou un antibiotique, Y représente de l'hydrogène et le groupement
EMI1.2     
 représente le reste   d'une    molécule organique possédant une fonction aldéhyde ou bien le groupement
EMI1.3     
 représente le reste d'une molécule organique possédant une fonction cétone ou quinone.



   Les nouveaux composés de formule générale) sont   susceptibles d'applications thérapeutiq ues.   



   Les sels de tétracycline des méta-sulfo et para-sulfobenzoyl-hydrazones du 5-nitro furfuraldéhyde peuvent être utilisés pour le traitement des staphylococcies, des streptococcies, des infections à Gram négatif (Escherichia Coli,   Klebsiella    Pneumoniae) et des champignons pathogènes. Enfin ils ne sont pas dépourvus d'activité vis-à-vis du bacile de Koch. De plus, il a été constaté que ces sels de tétracycline présentent une nette synergie dont l'efficacité a été démontrée in vivo et in vitro vis-à-vis de nombreuses souches cliniques à Gram positif ou négatif.

   Leur efficacité thérapeutique est supérieure à celle du chlorhydrate de   tétracyciine.    En outre, ils présentent le grand avantage par rapport aux autres dérivés de tétracycline de ne pas favoriser le développement de Candica   albicans    responsable des phénomènes toxi  ques    survenant lors des thérapeutiques prolongées avec des dérivés de la tétracycline.



   Le procédé de préparation des composés de formule générale   I,    objet de 1'invention, est caractérisé en ce que   1'on    fait réagir un composé de   formule genérale 11   
EMI1.4     
 dans laquelle R représente un cation métallique ou une base organique et Y et Z ont la signification indiquée précédemment, dans un solvant polaire ou un mélange de solvants polaires avec un sel d'un alcaloide ou d'un antibiotique et isole le composé correspondant.



   Le procédé de 1'invention est effectué avantageusement par réaction entre un sel soluble dans 1'eau de   l'alcalolde    ou de l'antibiotique et un sel solublc dans   l'eau    de   Fhydrazone    choisie.



   C'est ainsi qu'en mélangeant, par exemple, une solution aqueuse du sel de lithium de la   méta-sulfobenzoyl-      hydrazone    du 5-nitro furfuraldéhyde, à une solution aqueuse de chlorhydrate de tétracycline, on obtient le sel de tétracycline de la   méta-sulfobenzoyl-hydrazone    du   5-nitro-furfuraldéhyde    qui s'insolubilise.

   De même. à partir du sel de lithium de   la para-sulfobenzoyl-hydra-    zone du 5-nitro   furfuraldéhyde,    on obtient le sel de tétracycline de la   para-sulfobenzoyl-hydrazone    du   S-nitre      furfuraldéhyde.    On peut également préparer   d'une    manière analogue les sels de para-ou   meta-sulfobenzoyl-    hydrazone du 5-nitro furfuraldéhyde et de nombreux antibiotiques ou alcaloïdes à poids moléculaire élevé.



   Les sels d'antibiotiques des   méta-sulfo    et para-sulfo  henzoyl-hydrazones    du 5-nitro furfuraldéhyde, par exemple, peuvent, en vue d'applications thérapeutiques, être employés sous différentes formes pharmaceutiques. Ils sont alors utilisés par voie buccale, transcutanée ou par voie locale en application topique sur la peau et les muqueuses ou par voie rectale.



   IIs peuvent se présenter sous forme de solutions ou cle suspensions injectables, conditionnées en ampoules. en flacons à prises multiples, de comprimés, de comprimés enrobés, de poudre aromatisée, de   granulés, d'émul-    sions, de sirops, de suppositoires, d'ovules, de comprimés   intravaginaux.    de pommades, de crèmes, de gouttes nasales ou auriculaires, de collyre, de collutoire et de poudres topiques en pulvérisations.



   La posologie utile s'échelonne entre 200   mg    et 700   mg    par prise et 1 à 5 g par jour chez l'adulte en fonction de la voie d'administration.



   Les formes pharmaceutiques telles que solutions ou suspensions injectables, comprimés, comprimés enrobés, poudre aromatisée, granulés, émulsions, sirops, suppositoires,   ovules, comprimes intravaginaux, pommades,    crèmes, gouttes nasales ou auriculaires, collyre, collutoire et poudres topiques en pulvérisations. sont préparées selon les procédés usuels.



   Pour préparer les produits de départ de formule   IL    mis en jeu dans le procédé selon l'invention, on fait réagir, au sein d'un solvant polaire ou d'un mélange de solvants polaires, un méta-ou para-sulfobenzoyl-hydrazide de   formule IIf    :
EMI2.1     
 dans laquelle   R'représente    un atome d'hydrogène, un cation métallique ou une base organique, en présence   d'un    sel d'acide carboxylique d'un métal ou d'un sel d'acide carboxylique d'une base organique, avec un composé possédant une ou plusieurs fonctions aldÚhyde. cétone ou quinone.



   On peut opérer la condensation du méta ou para  sulfobenzoyl-hydrazide    en milieu légèrement acide, le sel interne de l'hydrazide étant salifié à   1'aide d'un ace-    tate a ! calin ou   alcalino-terreux,    avec libération d'acide acétique.



   Dans ces conditions et en opérant en milieu aqueux ou   alcoolique, 1l réaction    de condensation peut être
 réalisée à froid ou à   I'aide      d'un    léger et court chauffage. On peut également salifier la fonction sulfonique de   drazone    par une base organique quelconque suivant le degré de solubilité recherché, les sels de   diéthyi-    amine ou   d'cthanolamine etant particulièrement solubles    dans l eau ou les alcools.



   Une manière commode d'effectuer cette réaction consiste à dissoucire le   métra-ou      para-sulfobenzoyl-    hydrazide   dana 1'eau    en présence du sel d'acide carboxylieue du métal ou de lit base organique utilisés, puis à ajouter un alcool tel que le méthanol ou l'Úthanol et enfin le composé   carbonyl éventuellement    en solution dans un alcool. Comme sel métallique d'acide carboxylique, on utilise   avantageusement) es acétates    ou pro  pionates    d'ammonium, de lithium ou de sodium et comme sels de bases organiques, les acétates ou propionates d'Úthanolamine. de triÚthanolamine. de   diéthyl-    amine.



   Quant aux   métra-et      para-sulfobenzoyl-hydrazides de    formule   I f I,    ils peuvent être obtenus par le procédé décrit dans le brevet français   N# 1526954   
Example1:    . Sel de tétracycline   
 de la meta-sulfobenzoyl-hydrazone
 du 5-nitro furfuraldÚhyde
 A une solution de   8g    de chlorhydrate de tétracycline   dans 100cm# d'eau.    on ajoute une solution de   5,      74g    cle sel de lithium de la mÚta-sulfobenzoyl-hydrazone du
 5-nitro furfuraldéhyde dans   350cm : 3 d'eau.    Le précipite
 formé est essoré, avé à 1'eau et séché.



   On obtient ainsi 6,   95 g    de sel de tétracycline de la
   méta-sulfobenzoyl-hydrazone    du 5-nitro furfuraldéhyde.



   F. =   190-220)      C.      [a]@ = -149  (c=1%. diméthylforma-   
 mide).



   Ce composé est aisément   soluble à 4 g    par litre dans
   1'eau    et à 25 g par litre dans le méthanol.



   Analyse : C34H33N5SO15 = 783, 71
 Calculé : C% 52. 10   H O/o 4.    24   N"/n 8. 94 S"/o 4.    09
 Trouvé   51. 9      4,    5   8,    7   4,    2
Spectre U.V. (Úthanol)
   Infl. vers 220 m@ (@ =    28 750)
   # max. à 270 m@ (@    = 27   800)   
   ,. max. à    363 mu   (a = 3    600)
 Pour autant que   @on    sache, ce produit n'est pas décrit dans la littérature.



  Example II.



   Sel de tetracycline
   tle    la para-sulfobenzoyl-hydrazone
 du 5-nitro furfuraldÚhyde
 On ajoute une solution de 1, 07 g de sel de lithium de   la para-sulfobenzoyl-hydrazone    du 5-nitro   furfuraldéhycle    dans 30cm3 d'eau à une solution   de 1, 23 g    de   chlorhy-    drate de tétracycline dans   40cm8 d'eau, essore le pr-      cipité,    le lave   a 1'eau    et le sèche sous vide à température ambiante : on obtient   1, 1    g de sel de tétracycline de   la      para-sulfobenzoyl-hydrazone    du 5-nitro   furfuraldéhyde.   



  Analyse: C34H33N3SO15=783, 71
CalculÚ: C%52, 10 H% 4, 24 N% 8.94 5% 4,09
Trouvé : 51, 9   4, 6 8. 6 4, 1      Spectre U. V. (éthanol)    :
   ì. max. à    222-223   mu fF =    environ   25 100)       max. Ó 269-270 m@ (@ environ 28 200)   
   i. max. a    362 mu environ 38   400)    
 Pour autant que l'on sache, ce compose n'est pas décrit dans la littérature.



      PREPARATION   
 DES PRODUITS DE DÉPART
 Sel de   lithiiiliz   
 de la mÚta-sulfobenzoyl-hydrazone
   dit    5-nitro   ftirfitraldghyde   
   22g    de   méta-sulfobenzoyl-hydrazide    et   12g d'acé-      tate de lithium cristallisé    sont additionnes de 100 cm'' de méthanol à   10 lo    d'eau.

   On dissout par chauffage, filtre et refroidit le filtrat vers   20   C,    ajoute 14,1 g de 5-nitro   furfuraldéhyde      redistillé    en solution dans 100cm3 de méthanol absolu, maintient trois heures à   20  C a    l'obscurité, puis en glacière, essore, lave avec   150ci    de méthanol glacé, puis à l'éther, sèche dans le   :    on obtient 29 g de produit cherché.



   A la température ordinaire, ce sel est soluble dans   )'eau.   



   Pour autant que   l'on    sache, ce composé n'est pas décrit dans la littérature.



   Sel   de lithium   
 de la pura-sulfobenzoyl-hydrazone
 dit 5-nitro furfuraldÚhyde
   I I    g de para-sulfobenzoyl-hydrazide et 6 g d'acétate de lithium cristallisé sont dissous dans 50cm3 d'eau: on refroidit, ajoute 7g de 5-nitro furfuraldéhyde dans 100   cl3    de méthanol absolu, à froid, laisse reposer quatre heures à la température ordinaire à l'obscurité, puis en glacière. On essore, lave à l'éthanol, puis à   t'éther.   



   Le composé cristallise avec quatre   molécules d'cau.   



   La solubilitÚ du sel solvatÚ avec de l'eau est d'environ 2, 5% dans l'eau.



   Pour autant que   l'on    sache, ce composé n'est pas décrit dans la littérature.




  



   Process for the preparation of alkaloid or antibiotic salts of meta- or para-sulfobenzoyl-hydrazones
 The invention relates to a process for preparing novel alkaloid and antibiotic salts of meta para-sulfobenzoyl-hydrazones of general formula 1:
EMI1.1
 in which X represents an alkaloid or an antibiotic, Y represents hydrogen and the group
EMI1.2
 represents the remainder of an organic molecule having an aldehyde function or else the group
EMI1.3
 represents the remainder of an organic molecule having a ketone or quinone function.



   The new compounds of general formula) are capable of therapeutic applications.



   The tetracycline salts of the meta-sulfo and para-sulfobenzoyl-hydrazones of 5-nitro furfuraldehyde can be used for the treatment of staphylococci, streptococcal disease, gram-negative infections (Escherichia Coli, Klebsiella Pneumoniae) and pathogenic fungi. Finally, they are not devoid of activity with respect to Koch's bacillus. In addition, it has been observed that these tetracycline salts exhibit a clear synergy, the efficacy of which has been demonstrated in vivo and in vitro with respect to numerous clinical strains with Gram positive or negative.

   Their therapeutic efficacy is superior to that of tetracyciine hydrochloride. In addition, they have the great advantage over other tetracycline derivatives of not promoting the development of Candica albicans responsible for the toxic phenomena occurring during prolonged therapy with tetracycline derivatives.



   The process for preparing the compounds of general formula I, object of the invention, is characterized in that a compound of general formula 11 is reacted.
EMI1.4
 in which R represents a metal cation or an organic base and Y and Z have the meaning indicated above, in a polar solvent or a mixture of polar solvents with a salt of an alkaloid or of an antibiotic and isolates the corresponding compound.



   The process of the invention is advantageously carried out by reaction between a water soluble salt of the alkaloid or antibiotic and a water soluble salt of the chosen hydrazone.



   Thus, by mixing, for example, an aqueous solution of the lithium salt of meta-sulfobenzoyl-hydrazone of 5-nitro furfuraldehyde, with an aqueous solution of tetracycline hydrochloride, one obtains the tetracycline salt of meta -sulfobenzoyl-hydrazone of 5-nitro-furfuraldehyde which insolubilizes.

   The same. from the lithium salt of the para-sulfobenzoyl-hydrazone of 5-nitro furfuraldehyde, the tetracycline salt of the para-sulfobenzoyl-hydrazone of S-nitre furfuraldehyde is obtained. The para-or meta-sulfobenzoyl-hydrazone salts of 5-nitro furfuraldehyde and many high molecular weight antibiotics or alkaloids can also be prepared in an analogous manner.



   Antibiotic salts of the meta-sulfo and para-sulfo henzoyl hydrazones of 5-nitro furfuraldehyde, for example, can, for therapeutic purposes, be employed in various pharmaceutical forms. They are then used orally, transcutaneously or locally in topical application to the skin and mucous membranes or rectally.



   They can be in the form of injectable solutions or suspensions, packaged in ampoules. in multi-dose bottles, tablets, coated tablets, flavored powder, granules, emulsions, syrups, suppositories, ova, intravaginal tablets. ointments, creams, nasal or ear drops, eye drops, mouthwash and topical powder sprays.



   The useful dosage ranges between 200 mg and 700 mg per dose and 1 to 5 g per day in adults depending on the route of administration.



   Pharmaceutical forms such as injectable solutions or suspensions, tablets, coated tablets, flavored powder, granules, emulsions, syrups, suppositories, ova, intravaginal tablets, ointments, creams, nasal or ear drops, eye drops, mouthwash and topical powders in sprays. are prepared according to the usual methods.



   To prepare the starting products of formula IL used in the process according to the invention, is reacted in a polar solvent or a mixture of polar solvents, a meta- or para-sulfobenzoyl-hydrazide of formula IIf:
EMI2.1
 in which R 'represents a hydrogen atom, a metal cation or an organic base, in the presence of a carboxylic acid salt of a metal or of a carboxylic acid salt of an organic base, with a compound having one or more aldÚhyde functions. ketone or quinone.



   The meta or para sulfobenzoyl-hydrazide can be condensed in a slightly acidic medium, the internal salt of the hydrazide being salified with the aid of an ace- tate! calin or alkaline earth, with release of acetic acid.



   Under these conditions and by operating in an aqueous or alcoholic medium, the condensation reaction can be
 carried out cold or using a light and short heating. The sulfonic function of drazone can also be salified with any organic base depending on the desired degree of solubility, the diethylamine or octhanolamine salts being particularly soluble in water or alcohols.



   A convenient way to carry out this reaction is to dissolve the metra- or para-sulfobenzoyl-hydrazide in water in the presence of the carboxylic acid salt of the metal or organic base bed used, followed by adding an alcohol such as methanol. or ethanol and finally the carbonyl compound optionally in solution in an alcohol. As the metal salt of carboxylic acid, use is advantageously made of ammonium, lithium or sodium acetates or propionates, and as salts of organic bases, acetates or propionates of ethanolamine. triÚthanolamine. of diethylamine.



   As for the metra- and para-sulfobenzoyl-hydrazides of formula I f I, they can be obtained by the process described in French patent N # 1526954
Example1:. Tetracycline salt
 meta-sulfobenzoyl-hydrazone
 5-nitro furfuraldÚhyde
 Has a solution of 8g of tetracycline hydrochloride in 100cm # of water. a solution of 5.74g of the lithium salt of the meta-sulfobenzoyl-hydrazone of the
 5-nitro furfuraldehyde in 350cm: 3 of water. The precipitate
 formed is drained, washed with water and dried.



   In this way 6.95 g of tetracycline salt of the
   5-nitro furfuraldehyde meta-sulfobenzoyl-hydrazone.



   F. = 190-220) C. [a] @ = -149 (c = 1%. Dimethylforma-
 mide).



   This compound is readily soluble at 4 g per liter in
   Water and 25 g per liter in methanol.



   Analysis: C34H33N5SO15 = 783.71
 Calculated: C% 52. 10 H O / o 4. 24 N "/ n 8. 94 S" / o 4. 09
 Found 51. 9 4, 5 8, 7 4, 2
U.V. spectrum (ethanol)
   Infl. around 220 m @ (@ = 28,750)
   # max. at 270 m @ (@ = 27,800)
   ,. max. at 363 mu (a = 3600)
 As far as is known, this product is not described in the literature.



  Example II.



   Tetracycline salt
   para-sulfobenzoyl-hydrazone
 5-nitro furfuraldÚhyde
 A solution of 1.07 g of lithium salt of para-sulfobenzoyl-hydrazone of 5-nitro furfuraldehycle in 30 cm3 of water is added to a solution of 1.23 g of tetracycline hydrochloride in 40 cm8 of water, The precipitate is filtered off, washed with water and dried under vacuum at room temperature: 1.1 g of the tetracycline salt of the para-sulfobenzoyl-hydrazone of 5-nitro furfuraldehyde are obtained.



  Analysis: C34H33N3SO15 = 783.71
Calculation: C% 52, 10 H% 4, 24 N% 8.94 5% 4.09
Found: 51.9 4, 6 8. 6 4, 1 U. V. Spectrum (ethanol):
   ì. max. at 222-223 mu fF = approx. 25,100) max. Ó 269-270 m @ (@ around 28,200)
   i. max. at 362 mu approximately 38,400)
 As far as we know, this compound is not described in the literature.



      PREPARATION
 STARTING PRODUCTS
 Lithiiiliz salt
 meta-sulfobenzoyl-hydrazone
   said 5-nitro ftirfitraldghyde
   22 g of meta-sulfobenzoyl-hydrazide and 12 g of crystallized lithium acetate are added 100 cm 3 of methanol to 10 l of water.

   The filtrate is dissolved by heating, filtered and cooled to around 20 ° C., 14.1 g of 5-nitro furfuraldehyde redistilled in solution in 100 cm3 of absolute methanol are added, kept for three hours at 20 ° C. in the dark, then in a cooler, drained, washed with 150 cc of ice-cold methanol, then with ether, dried in: 29 g of the desired product are obtained.



   At room temperature, this salt is soluble in water.



   As far as we know, this compound is not described in the literature.



   Lithium salt
 pura-sulfobenzoyl-hydrazone
 said 5-nitro furfuraldÚhyde
   II g of para-sulfobenzoyl-hydrazide and 6 g of crystallized lithium acetate are dissolved in 50 cm3 of water: cooled, add 7 g of 5-nitro furfuraldehyde in 100 cl3 of absolute methanol, cold, left to stand for four hours at room temperature in the dark, then in a cooler. It is filtered off, washed with ethanol and then with ether.



   The compound crystallizes with four molecules of water.



   The solubility of solvated salt with water is about 2.5% in water.



   As far as we know, this compound is not described in the literature.


 

Claims (1)

REVENDICATION Procède de préparation de sels d'alcalo¯des et d'antibiotiques de formule géncrale 1 : EMI3.1 dans laquelle X représente un alcaloide ou un antibio- tique, Y représente de lhydrogène et le groupement = CH-Z représente le reste d'une molécule organique possédant une fonction aldéhyde, ou bien le groupement EMI3.2 représente le reste d'une molécule organique possédant une fonction cétone ou quinone, caractérisé en ce que l'on fait réagir un composé de formule générale 11 EMI3.3 dans laquelle R représente un cation métallique ou une base organique et Y et Z ont la signification indiquée ci-de ; CLAIM Process for the preparation of alkaloid salts and antibiotics of general formula 1: EMI3.1 in which X represents an alkaloid or an antibiotic, Y represents hydrogen and the group = CH-Z represents the remainder of an organic molecule having an aldehyde function, or the group EMI3.2 represents the remainder of an organic molecule having a ketone or quinone function, characterized in that a compound of general formula 11 is reacted EMI3.3 in which R represents a metal cation or an organic base and Y and Z have the meaning indicated above; sus. dans un solvant polaire ou un mélange de solvants polaires avec un sel d'un alcaloide ou d'un anti- biotique et isole le compose correspondant. sus. in a polar solvent or a mixture of polar solvents with a salt of an alkaloid or an antibiotic and isolates the corresponding compound. SOUS-REVENDICATION Procède selon la revendication, caractérisé en ce que l'on fait agir en solution aqueuse le chlorhydrate de tetracycline sur le sel de lithium de la meta-ou para su) fobenzoyi-hydrazone du 5-nitro furfuraldÚhyde et obtient le sel de téìracycline de la mélia-ou para-sulfobenzoyl-hydrazone du 5-nitro furfuraldéhyde correspondant. SUB-CLAIM Process according to claim, characterized in that the tetracycline hydrochloride is made to act in aqueous solution on the lithium salt of the meta- or para su) fobenzoyi-hydrazone of 5-nitro furfuraldÚhyde and the téìracycline salt of the melia- or para-sulfobenzoyl-hydrazone of the corresponding 5-nitro furfuraldehyde.
CH1786969A 1966-12-26 1967-12-11 Process for the preparation of alkaloid or antibiotic salts of meta- or para-sulfobenzoyl-hydrazones CH489473A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR88828A FR1526955A (en) 1966-12-26 1966-12-26 New hydrazones and method of preparation
FR100012A FR6359M (en) 1966-12-26 1967-03-23
CH1729967A CH484066A (en) 1966-12-26 1967-12-11 Process for preparing new hydrazones

Publications (1)

Publication Number Publication Date
CH489473A true CH489473A (en) 1970-04-30

Family

ID=27177591

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1786969A CH489473A (en) 1966-12-26 1967-12-11 Process for the preparation of alkaloid or antibiotic salts of meta- or para-sulfobenzoyl-hydrazones

Country Status (1)

Country Link
CH (1) CH489473A (en)

Similar Documents

Publication Publication Date Title
EP0606024A1 (en) Erythromycin derivatives, their process of preparation and their application as medicaments
BE851310A (en) NEW DERIVATIVES OF TETRAHYDRO-EQUINOCANDIN B
FR2601368A1 (en) NITROFURAN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
CH622264A5 (en) Process for the preparation of new oximes, syn isomers, derived from 7-(aminothiazolylacetamido)cephalosporanic acid
CH624952A5 (en)
CA1115704A (en) Process for the preparation of derivatives of 1-aza bicyclo [2,2,2] octane and of their intermediates and use as pharmaceutical compounds
CH638221A5 (en) OXIMES DERIVED FROM 3-SUBSTITUTED 7-AMINO ACID THIAZOLYL ACETAMIDO CEPHALOSPORANIQUE, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CH489473A (en) Process for the preparation of alkaloid or antibiotic salts of meta- or para-sulfobenzoyl-hydrazones
CA1094547A (en) Preparation process of 3-carbamoyloxymethyl 7-(amino thyazolyl acetamido) cephalosporanic acid derivatives
CA1034576A (en) Processes for the preparation of new piperazine derivatives
EP0176444B1 (en) Process for the preparation of derivatives of 4h-1,2,4-triazole, triazoles so obtained, their use as medicaments, and pharmaceutical compositons containing them
Wolfrom et al. ALDEHYDO-l-ARABINOSE TETRA-ACETATE1
FR2614022A1 (en) NEW 20,21-DINOREBURNAMENINE 17-AZA DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THE NEW INTERMEDIATES THUS OBTAINED, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS COMPRISING THEM
CH529153A (en) 3-amino-pyrazolo (1,2b)-phthalazine-1,5-(ioh)
CA1200554A (en) Process for preparing new aminomethyl 14-indole-4- methanol derivatives and the salts thereof
CA1099290A (en) Process for the preparation of 7-amino-6,7-dihydro (5h) benzocyclohepten
EP0008965A2 (en) Aminoglycosides derived from desoxystreptamin and their salts, their method of preparation and pharmaceutical compositions containing them
CA1123824A (en) Oximes derivatives of the 7-amino-thiazolyl-acetamido- cephalosporanic acid, preparation process and use as a drug
CH467245A (en) Process for the preparation of esters of tetracycline, 7-chlorotetracycline and 5-hydroxytetracycline
FR2544316A1 (en) 8-CYANO-6,7-DIHYDRO-5-METHYL-1-OXO-1H, 5H-BENZO (IJ) QUINOLIZIN-2-CARBOXYLIC ACIDS, THEIR PREPARATION AND USES THEREOF
EP0170937B1 (en) Double salt of desoxyfructosyl-serotonine and of creatinine, its preparation and medicaments containing it
BE897217A (en) NEW ANTI-INFLAMMATORY, ANALGESIC AND ANTIPYRETIC DRUG BASED ON (P-CHLOROBENZOYL-1, METHYL- 2- Methoxy-5) Indole-3 P-Acetamidophenol Acetate
EP0070049A1 (en) Derivative of acetylsalicylic acid having an analgetic, antipyretic, antiphlogistic and bronchosecretolytic activity
BE903568A (en) NOVEL CHEMICAL COMPOUNDS WITH ANTIPHLOGISTIC, ANTISEPTIC AND DETERGENT ACTIVITIES
CH325297A (en) Process for preparing a new antibiotic

Legal Events

Date Code Title Description
PL Patent ceased